GlassScriptPhysician profile
Yemuna E Satya
NPI 1790781771
$4,367.24
in general payments reported to CMS, 2019-2025
30 companies · $768 in 2025
The $768 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $313 · 2021: $213 · 2022: $726 · 2023: $1,218 · 2024: $812 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,604 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,603.93 |
| Education | $194.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $455.68 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $405.94 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $386.90 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Sanofi-Aventis U.S. LLC | $246.26 | 2019-2023 | |
| Cvrx, INC. | $243.57 | 2022-2024 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $227.51 | 2024-2025 | Amvuttra, Onpattro |
| Boston Scientific Corporation | $221.71 | 2019-2025 | Watchman Access System, Cds - Mct/Cem Monitoring |
| Amgen INC. | $210.54 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $197.57 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.79 | 2019-2024 | Jardiance |
| Philips North America LLC | $182.03 | 2022-2025 | (Ck4) Mcot, Ecc Solutions, (Ck6) Holter |
| Bayer Healthcare Pharmaceuticals INC. | $179.71 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $154.48 | 2022-2024 | Verquvo |
| Janssen Scientific Affairs, LLC | $137.26 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.54 | 2022-2024 | Lifevest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $119.71 | 2022-2023 | Assure Wcd |
| Novo Nordisk INC | $115.29 | 2023-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $100.79 | 2019-2022 | |
| Abbott Laboratories | $100.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $79.34 | 2022-2024 | Eliquis, Camzyos |
| Irhythm Technologies, INC. | $72.76 | 2022-2023 | Zio Xt Patch |
| Kiniksa Pharmaceuticals International, Plc | $57.01 | 2024 | Arcalyst |
| Akcea Therapeutics, INC. | $36.04 | 2020 | |
| Braemar Manufacturing, LLC | $25.35 | 2019 | |
| Janssen Biotech, INC. | $21.64 | 2025 | Tremfya |
| Scpharmaceuticals INC. | $21.55 | 2024 | |
| Cardiovascular Systems INC. | $17.09 | 2019 | |
| Portola Pharmaceuticals, LLC | $16.07 | 2019 | |
| G Medical Diagnostic Services, INC. | $12.11 | 2022 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yemuna Satya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.